FDA okayed the marketing of a new continuous glucose monitoring system for diabetics—the first to be used as part of an integrated system with other compatible medical devices and electronic interfaces.
President Donald Trump was expected to announce a new plan to combat the opioid crisis, even as a recent study found that prescription opioids were not as effective as over-the-counter medications for pain management.
During the worst flu season in years, FDA is warning consumers about fraudulent and counterfeit flu and antiviral products from online pharmacies.
In a rare move, pharmaceutical manufacturers voluntarily recalled their drug to treat multiple sclerosis after reports of serious brain inflammation in patients.
FDA said the manufacturer of dietary supplements containing kratom, a natural opioid used to treat opioid use disorder, agreed to destroy the supplements, and is again warning the public about kratom.
FDA should provide better education about biosimilar drugs on the agency’s web site dedicated to biosimilars, a patient advocacy group said.
A pharmacist organization is among the supporters of a new Medicare Part D proposal, which calls for a 7-day supply limit on opioid prescriptions.
FDA is adding a Boxed Warning, its most prominent warning, on a liver disease medicine.
A patient advocacy group is criticizing the hefty price tag of a new treatment for blindness.
Patients with systemic lupus erythematosus often self-manage their corticosteroid medication without the consent of their healthcare providers, according to a recent multicountry survey.